A5018004849- Cancer Treatment and Pharmacology
- Chemokine receptors and signaling
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Blood disorders and treatments
- Ancient and Medieval Archaeology Studies
- Historical Gender and Feminism Studies
- Vascular Anomalies and Treatments
- Historical and Archaeological Studies
- Cell Adhesion Molecules Research
- Cinema and Media Studies
- Antimicrobial Resistance in Staphylococcus
- Multiple Myeloma Research and Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Nosocomial Infections in ICU
- Qualitative Research Methods and Ethics
- Synthesis and biological activity
- Contemporary Literature and Criticism
- Monoclonal and Polyclonal Antibodies Research
- Cervical Cancer and HPV Research
- Child Welfare and Adoption
- Folklore, Mythology, and Literature Studies
- Neutropenia and Cancer Infections
- Radiology practices and education
- Evaluation of Teaching Practices
Teesside University
2021
Polyphor (Switzerland)
2018-2020
2606 Background: Balixafortide (B) is a potent antagonist of the chemokine receptor CXCR4. Preclinical evidence suggests that disrupting CXCR4 dependent pathways prevents development breast cancer metastases, enhances cytotoxic effect chemotherapy and immunotherapy, counteracts tumor cell evasion immune system. Encouraging safety efficacy data were published recently from ongoing Phase 1 trial investigating B + eribulin (E) in patients with HER2 negative MBC (Pernas S. et al. Lancet Oncol....
Abstract Staphylococcus aureus nasal carriers were randomized (1:1) to XF-73 or placebo gel, administered 5x over ∼24hrs pre-cardiac surgery. S. burden rapidly decreased after 2 doses (–2.2log 10 CFU/mL; –0.01log CFU/mL) and was maintained 6 days post-surgery. Among patients, 46.5% received post-operative anti-staphylococcal antibiotics versus 70% in ( P = 0.045).
Abstract Background: Balixafortide (B) is a potent CXCR4 antagonist. High levels correlate with aggressive metastatic phenotypes and poor prognosis in breast cancer (BC). Encouraging safety efficacy data were published from the Phase 1 trial investigating B + eribulin (E) patients HER2 negative BC1,2. The objective response rate (ORR), median progression free survival (PFS), overall (OS), 12, 18 24 month OS estimate who received E as 2nd line or later therapy respectively: 37.5%, 6.2 months,...
Reviewed by: George Sword’s Warrior Narratives: Compositional Processes in Lakota Oral Tradition by Delphine Red Shirt Debra K. S. Barker Tradition. By Shirt. Lincoln: University of Nebraska Press, 2016. vii + 214 pp. Appendixes, notes, references, index. $65.00 cloth. provides a valuable, culturally informed analysis selection texts authored Sword, one the most noteworthy historical figures spanning nineteenth and twentieth centuries. Serving as army scout, translator, captain military...
Reviewed by: Shaping Survival: Essays by Four American Indian Tribal Women Debra K. S. Barker (bio) Lanniko L. Lee, Florestine Kiyukanpi Renville, Karen Lone Hill, and Lydia Whirlwind Soldier . Women. Ed. Jack W. Marken Charles Woodard. Lanham MD: Scarecrow Press, 2001. ix + 221 pp. Glossary of D/Lakota words phrases, index. In the summer 2001 Elizabeth Cook-Lynn Professor Chuck Woodard South Dakota State University organized their yearly gathering for Lakota, Dakota, Nakota writers, Oak...
Legacies of the Ever Beating Heart:Delphine Red Shirt's Turtle Lung Woman's Granddaughter Debra K. S. Barker (bio) In her latest book, Granddaughter, Lakota writer Delphine Shirt presents kind unmediated as-told-to life narrative for which we have long awaited. Her book in fact two orally related stories, that mother, Lone Woman (Wiya Isnala), and great-grandmother, (Kheglezela Chaguwi). Serving as amanuensis then translator, edited a body family stories mother to language over period years....
Background: Balixafortide (B) is a highly selective antagonist of the chemokine receptor CXCR4. Clinical proof-of-concept in combination with eribulin (E) was achieved recent Phase 1 single arm dose-escalation trial patients metastatic HER2-negative breast cancer (NCT01837095). Safety and tolerability B E similar to that or monotherapy.Anti-cancer effects CXCR4 antagonists include sensitization tumor cells chemotherapy, suppression spread, inhibition angiogenesis, activation immune...
Abstract Background: Balixafortide (B) is a highly selective antagonist of the chemokine receptor CXCR4. Clinical proof-of-concept in combination with eribulin (E) was achieved recent Phase 1 single arm dose-escalation trial patients metastatic HER2-negative breast cancer (NCT01837095). Safety and tolerability B E similar to that or monotherapy. Anti-cancer effects CXCR4 antagonists include sensitization tumor cells chemotherapy, suppression spread, inhibition angiogenesis, activation immune...